Novanta Inc. (LON:0VAG)

London flag London · Delayed Price · Currency is GBP · Price in USD
168.27
-1.26 (-0.74%)
Jun 4, 2026, 4:34 PM GMT
Market Cap4.43B +24.3%
Revenue (ttm)761.38M +5.6%
Net Income40.70M -23.9%
EPS1.07 -27.6%
Shares Out n/a
PE Ratio108.72
Forward PE38.87
Dividendn/a
Ex-Dividend Daten/a
Volume788
Open167.70
Previous Close169.53
Day's Range162.38 - 168.54
52-Week Range99.31 - 176.49
Beta1.62
Analystsn/a
Price Targetn/a
Earnings DateMay 11, 2026

About Novanta

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment s... [Read more]

Industry Hardware, Equipment & Parts
Sector Technology
Founded 1968
Employees 3,000
Stock Exchange London Stock Exchange
Ticker Symbol 0VAG

Financial Performance

In 2025, Novanta's revenue was $980.60 million, an increase of 3.30% compared to the previous year's $949.25 million. Earnings were $53.83 million, a decrease of -16.01%.

Financial numbers in USD Financial Statements

News

Novanta Transcript: William Blair 46th Annual Growth Stock Conference

Portfolio now over 50% medical, with recurring revenue and reduced cyclicality. Growth driven by innovation in surgical robotics, advanced automation, and light-based technologies, with strong M&A activity and a focus on high-growth, secular markets. Margin expansion and cash flow conversion remain priorities.

1 day ago - Transcripts

Novanta Transcript: AGM 2026

The meeting covered board introductions, review of 2025 financials, and voting on director elections, executive compensation, and auditor appointment. All proposals passed, and no shareholder questions were raised.

7 days ago - Transcripts

Novanta to Present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...

20 days ago - Business Wire

Novanta to Present at Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...

20 days ago - Business Wire

Novanta price target raised to $173 from $144 at Baird

Baird raised the firm’s price target on Novanta (NOVT) to $173 from $144 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results showing…

22 days ago - TheFly

Novanta Earnings Call Transcript: Q1 2026

Q1 2026 saw double-digit bookings and revenue growth across all businesses, with strong cash flow and margin expansion despite tariff and cost headwinds. Guidance for 2026 was raised, supported by robust demand in AI, medical, and automation markets, and a strong acquisition pipeline.

23 days ago - Transcripts

Novanta Earnings release: Q1 2026

Novanta released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.

23 days ago - Filings

Novanta Quarterly report: Q1 2026

Novanta has published its Q1 2026 quarterly earnings report on May 12, 2026.

23 days ago - Filings

Novanta reports Q1 adjusted EPS 81c, consensus 78c

Reports Q1 revenue $257.7M, consensus $253.4M. “Novanta (NOVT) delivered another quarter of excellent bookings, growing 37% year-over-year and representing a 1.10 book-to-bill ratio, driven by continu...

23 days ago - TheFly

Novanta sees Q2 adjusted EPS 81c-86c, consensus 86c

Sees Q2 revenue $259M-$264M, consensus $257.08M.

23 days ago - TheFly

Novanta backs FY26 adjusted EPS view $3.50-$3.65, consensus $3.56

Raises FY26 revenue view to $1.04B-$1.055B from $1.03B-$1.05B, consensus $1.04B.

23 days ago - TheFly

Novanta Announces Financial Results for the First Quarter 2026

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...

24 days ago - Business Wire

Novanta Proxy statement: Proxy filing

Novanta filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.

5 weeks ago - Filings

Novanta Inc. Announces Schedule of First Quarter 2026 Earnings Release and Conference Call

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 resul...

7 weeks ago - Business Wire

Novanta upgraded to Outperform from Neutral at Baird

Baird analyst Quinn Fredrickson upgraded Novanta (NOVT) to Outperform from Neutral with a price target of $144, down from $150. The firm remains positive on the advanced industrial technology group,…

2 months ago - TheFly

Novanta Joins NVIDIA Halos AI Systems Inspection Lab

BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) announced today that it has joined NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited inspection...

2 months ago - Business Wire

Novanta price target raised to $150 from $138 at Baird

Baird analyst Robert Mason raised the firm’s price target on Novanta (NOVT) to $150 from $138 and keeps a Neutral rating on the shares. The firm updated its model following…

3 months ago - TheFly

Novanta Earnings Call Transcript: Q4 2025

Record 2025 revenue and bookings, strong new product growth, and double-digit profit gains were achieved, though margins and cash flow were temporarily pressured by manufacturing transitions. 2026 guidance calls for 4–6% organic growth, margin expansion, and robust acquisition capacity.

3 months ago - Transcripts

Novanta Annual report: Q4 2025

Novanta has published its Q4 2025 annual report on February 24, 2026.

3 months ago - Filings

Novanta Earnings release: Q4 2025

Novanta released its Q4 2025 earnings on February 24, 2026, summarizing the period's financial results.

3 months ago - Filings

Novanta Annual report: Q4 2025

Novanta has published its Q4 2025 annual report on February 24, 2026.

3 months ago - Filings

Novanta reports Q4 adjusted EPS 91c, consensus 88c

Reports Q4 revenue $258M, consensus $260.72M. “Novanta (NOVT) exceeded expectations for revenue in the fourth quarter, delivering accelerated reported growth of 9% and a return to positive organic gro...

3 months ago - TheFly

Novanta sees Q1 adjusted EPS 75c-80c, consensus 83c

Sees Q1 revenue $250M-$255M, consensus $253.32M.

3 months ago - TheFly

Novanta sees 2026 adjusted EPS $3.50-$3.65, consensus $3.61

Sees 2026 revenue $1.03B-$1.05B, consensus $1.04B.

3 months ago - TheFly

Novanta Announces Financial Results for the Fourth Quarter and Full Year 2025

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...

3 months ago - Business Wire